COTI-2, an anti-cancer drug with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation.
Molecular Weight | 366.48 |
CAS Number | 1039455-84-9 |
Solubility (25°C) | DMSO 5 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[5] Michael J Duffy, et al. Eur J Cancer. Mutant p53 as a target for cancer treatment
Related p53 Products |
---|
BAY 1892005
BAY 1892005, a p53 protein modulator, is active on p53 condensates and does not lead to mutant p53 reactivation. |
FOXO4-DRI
FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of FOXO4 and p53. |
p53 (17-26)
p53 (17-26) is amino acids 17 to 26 fragment of p53. |
Azurin p28 peptide
Azurin p28 peptide is a tumor-penetrated antitumor peptide. |
INV-102
INV-102 is a p53 and Pax6 activator that can be used in studies related to dry eye. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.